SD36 is an experimental anticancer drug which acts as a proteolysis targeting chimera (PROTAC) against the protein STAT3, acting by targeting this protein for destruction by cell maintenance enzymes. It has been used by a Spanish group led by Mariano Barbacid, as part of a combination triple therapy alongside daraxonrasib and afatinib for treatment-resistant strains of pancreatic cancer, and is also widely used for research into the treatment of other cancers and the development of related drugs.